European Headache Federation (EHF) Guidelines for migraine management recommend the use of several monoclonal antibodies against calcitonin gene-related peptides or its receptors, including eptinezumab, erenumab, fremanezumab, and galcanezumab. The gene discussed is CALCA; the disease is migraine disorder.